<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02468414</url>
  </required_header>
  <id_info>
    <org_study_id>MG-EP-RF-04</org_study_id>
    <nct_id>NCT02468414</nct_id>
  </id_info>
  <brief_title>TARGTEPO Treatment for Anemia in PD US Trial</brief_title>
  <official_title>Safety &amp; Efficacy of Prolonged Physiologic EPO Level Treatment of Anemia in ESRD Patients Undergoing Peritoneal Dialysis Using MDGN201 TARGTEPO</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aevi Genomic Medicine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medgenics Medical Israel Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aevi Genomic Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to assess safety and to evaluate the biologic activity of
      TARGTEPO treatment in Peritoneal Dialysis patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II, open-label study. Each patient will be administered with a targeted dose
      of EPO delivered via TARGTEPO.

      The targeted doses will be determined according to 2 cohorts as follows: Group A (18-25
      IU/Kg/day), Group B (35-45 IU/Kg/day). The objective is to evaluate safety and biologic
      activity of TARGTEPO treatment when maintaining Hb levels within the target range of 9-12
      g/dl. Biological activity assessments will include duration of TARGTEPO secretion as measured
      by serum EPO levels above baseline.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No statistical analysis was performed as only one subject was treated with MDGN201 TARGTEPO due
    to the Sponsor's decision to discontinue study.
  </why_stopped>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients Who Achieved Biological Activity of MDGN201 TARGTEPO Secretion as Measured by Serum EPO Levels Above Baseline.</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Anemia of End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>MDGN201 TARGTEPO secreting EPO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MDGN201 TARGTEPO secreting EPO</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MDGN201 TARGTEPO</intervention_name>
    <description>MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)</description>
    <arm_group_label>MDGN201 TARGTEPO secreting EPO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MDGN201 TARGTEPO</intervention_name>
    <description>MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)</description>
    <arm_group_label>MDGN201 TARGTEPO secreting EPO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult male or female subjects between 18 to 80 years of age at the time of screening
             visit.

          2. Subject diagnosed with anemia due to Chronic Kidney Disease (CKD) Stage 5 on
             peritoneal dialysis treatment for at least 6 months. Average Hgb during last month
             between 9 to 12g/dL. Stable dose of ESAs over the past month prior to enrollment.

          3. Hypertensive subjects are stable on anti HTN treatment for the past one month prior to
             enrollment and has Systolic blood pressure (BP) below 150 and Diastolic BP below 90
             upon enrollment.

          4. Kt/V &gt; 1.

          5. INR ≤ 1.2.

          6. Serum albumin &gt; 3.2.

          7. Subjects with adequate iron stores (transferrin saturation &gt; 20.0% and/or ferritin
             &gt;100 ng/ml).

          8. Capable of providing signed written informed consent to participate in the study.

        Exclusion Criteria:

          1. Uncontrolled hypertension (defined as diastolic blood pressure &gt; 110 mmHg or systolic
             blood pressure &gt; 180 mmHg during screening).

          2. Subjects who receive oral anti-coagulation treatment (e.g. warfarin).

          3. Subjects who receive acetylsalicylic acid (ASA) above 325 mg/day or patients who
             receive ASA treatment between 100mg/d and 325 mg/d who cannot discontinue it for 1
             week prior to each Harvest or Implantation Procedure.

          4. Congestive heart failure (New York Heart Association functional class III or IV).

          5. Grand mal seizures within 2 years of the Screening Visit.

          6. Clinical evidence of severe hyperparathyroidism as defined by parathyroid hormone
             (PTH) levels of &gt; 10 times the upper normal limits.

          7. Major surgery within 12 weeks of the Screening Visit.

          8. Systemic hematologic diseases (e.g., sickle cell anemia, thalassemia (excluding
             thalassemia minor), myelodysplastic syndromes, hematologic malignancy, myeloma,
             hemolytic anemia).

          9. Current systemic infection, active inflammatory disease, or malignancy under active
             treatment.

         10. Subjects known to have tested positive at any time in the past for antibodies to
             erythropoietic proteins.

         11. Subject has history of malignancy within the past 2 years prior to the Screening
             Visit, with the exception of basal cell carcinoma.

         12. Subjects with other concurrent severe and/or uncontrolled medical condition that could
             compromise participation in the study (i.e. active infection, uncontrolled diabetes,
             uncontrolled hypertension, congestive heart failure, unstable angina, ventricular
             arrhythmias, active ischemic heart disease, myocardial infarction within six months,
             uncompensated cirrhosis, active upper gastrointestinal (GI) tract ulceration).

         13. Subject is currently enrolled in, or has not yet completed a period of at least 30
             days or five half-lives of the investigational drug whichever is longer, since ending
             other investigational device or drug trial(s) prior to Screening Phase.

         14. Psychiatric, addictive, or any other disorder that compromises ability to provide
             informed consent for participation in this study.

         15. Female subjects of child-bearing potential and males that do not agree to use
             acceptable methods of contraception during the study.

         16. Pregnant or lactating female subjects.

         17. Chronic alcoholic or drug abuse subjects.

         18. Steroid or other immunosuppressive treatment (other than topical or inhaled steroids).

         19. Subjects unwilling or unable to comply with the study procedures.

         20. EPO-naïve subjects.

         21. Known sensitivity to gentamicin and amphotericin.

         22. History of chronic or active hepatitis B and/or C infection or positive serology at
             screening, and known positive Human Immunodeficiency Virus (HIV) or positive serology
             at screening.

         23. Subject had a blood transfusion within 84 days prior to Screening Visit.

         24. Subject has a date for renal transplantation.

         25. Refer to the United States Product Insert (USPI) - Depo-Medrol (DM) -
             Methylprednisolone Acetate - Injectable (Appendix A) for any concomitant drug taken by
             the patient, which its interactions with DM will warrant exclusion from this protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shany Blum, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Medgenics Medical Israel Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Advancement Center, PLLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <results_first_submitted>June 8, 2017</results_first_submitted>
  <results_first_submitted_qc>July 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 13, 2017</results_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peritoneal Dialysis</keyword>
  <keyword>End Stage Renal Disease</keyword>
  <keyword>Anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Early stage small feasibility study.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group A</title>
          <description>18-25 IU/Kg/day</description>
        </group>
        <group group_id="P2">
          <title>Group B</title>
          <description>35-45 IU/Kg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Successfully Screened</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Harvesting</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Implantation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Early Study Termination by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor in-vitro secreting TARGTs</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A</title>
          <description>TARGTEPO 18-25 IU/kg/day</description>
        </group>
        <group group_id="B2">
          <title>Group B</title>
          <description>TARGTEPO 35-45 IU/kg/day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patients Who Achieved Biological Activity of MDGN201 TARGTEPO Secretion as Measured by Serum EPO Levels Above Baseline.</title>
        <time_frame>52 weeks</time_frame>
        <population>No statistical analysis was performed as only one subject was treated with MDGN201 TARGTEPO due to the Sponsor's decision to discontinue study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>TARGTEPO 18-25 IU/kg/day</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>TARGTEPO 35-45 IU/kg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Who Achieved Biological Activity of MDGN201 TARGTEPO Secretion as Measured by Serum EPO Levels Above Baseline.</title>
          <population>No statistical analysis was performed as only one subject was treated with MDGN201 TARGTEPO due to the Sponsor's decision to discontinue study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group A</title>
          <description>TARGTEPO 18-25 IU/kg/day</description>
        </group>
        <group group_id="E2">
          <title>Group B</title>
          <description>TARGTEPO 35-45 IU/kg/day</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Viral Gasritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Local Contact Dermatitis, Right Upper Abdomen</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Should the Primary Investigator (PI) wish to publish the results of this study, the PI agrees to provide the Sponsor with a manuscript for review 60 days prior to submission for publication. The Sponsor retains the right to delete from the manuscript information that is confidential and proprietary and to object to suggested publication and/or its timing (at the Sponsor’s sole discretion).</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Garry A. Neil, MD</name_or_title>
      <organization>Aevi Genomic Medicine</organization>
      <phone>610-254-4208</phone>
      <email>garry.neil@aevigenomics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

